A novel activin signaling inhibitor for the treatment of pulmonary arterial hypertension:sotatercept
Sotatercept(MK-7962,ACE-011)is a novel fusion protein of the activin receptor ⅡA-FC(ActRⅡA-Fc)that targets and reverses pulmonary vascular remodeling caused by pulmonary arterial hypertension(PAH)by inhibiting activin signaling.Phase Ⅱ and Ⅲ clinical trials have demonstrated that sotatercept has a significant therapeutic effect on PAH,enhances the exercise capacity of patients with PAH,and exhibits good safety and tolerability,leading to its FDA approval for PAH treatment.This article offers an overview of the mechanism of action,pharmacokinetics,clinical efficacy,safety profile,dosage,drug interactions,and the latest research developments of sotatercept.
NETL
NSTL
万方数据
